Study Comparing Tan EndoGlide With the Busin Glide for Insertion of the Donor Graft in DSAEK
Not Applicable
- Conditions
- Endothelial Cell Loss With Different Insertion Devices
- Interventions
- Device: Busin Glide for delivery of the donor graftDevice: Use of the Tan EndoGlide to insert donor graft
- Registration Number
- NCT01284543
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
The Tan EndoGlide device results in less endothelial cell trauma during insertion of the donor corneal graft indicated by reduced endothelial cell loss at 1 year follow-up compared to the Busin glide.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
- Patients presenting with corneal decompensation requiring DSAEK with or without cataract surgery for visual rehabilitation.
- Clinical diagnosis include endothelial cell dysfunction secondary to Fuchs endothelial dystrophy, pseudophakic or aphakic bullous keratopathy, failed penetrating keratoplasty or DSAEK, iridocorneal endothelial syndrome or trauma.
- Ability to understand the nature of the procedure and give full informed consent.
- Patients who are able to comply with the standard DSAEK follow-up protocol at the Toronto Western Hospital.
Read More
Exclusion Criteria
- Patients with late stage corneal decompensation with stromal scarring unsuitable for DSAEK and therefore requiring penetrating keratoplasty.
- Patients with complex anterior segment pathology precluding successful DSAEK procedure.
- Patients not giving full informed consent to participate in the trial
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Busin glide delivery of donor graft Busin Glide for delivery of the donor graft Use of the Busin glide to insert the donor graft Tan EndoGlide for insertion of the donor graft Use of the Tan EndoGlide to insert donor graft Use of the Tan EndoGlide for insertion of the donor graft
- Primary Outcome Measures
Name Time Method Endothelial cell counts at 1, 3, 6 and 12 months postoperatively 1 year Best corrected visual acuity at 1, 3, 6, and 12 months postoperatively 1 year
- Secondary Outcome Measures
Name Time Method Complications of surgery 1 year
Trial Locations
- Locations (1)
Toronto Western Hospital
🇨🇦Toronto, Ontario, Canada